These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22354221)

  • 41. Lung cancer: alternative rearrangements--targeting ROS1 in NSCLC.
    Killock D
    Nat Rev Clin Oncol; 2014 Nov; 11(11):624. PubMed ID: 25311353
    [No Abstract]   [Full Text] [Related]  

  • 42. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 43. Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib.
    Jao K; Tomasini P; Labbe C; Doherty M; Shepherd FA
    J Thorac Oncol; 2015 Jun; 10(6):965-6. PubMed ID: 26001146
    [No Abstract]   [Full Text] [Related]  

  • 44. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.
    Kim YH; Ozasa H; Nagai H; Sakamori Y; Yoshida H; Yagi Y; Nakaoku T; Mishima M
    J Thorac Oncol; 2013 Sep; 8(9):e85-6. PubMed ID: 23945393
    [No Abstract]   [Full Text] [Related]  

  • 45. Did targeted therapy fail cyclooxygenase too?
    Csiki I; Johnson DH
    J Clin Oncol; 2006 Oct; 24(30):4798-800. PubMed ID: 17050864
    [No Abstract]   [Full Text] [Related]  

  • 46. Discovery of drug resistance biomarker could improve cancer treatment.
    Pharmacogenomics; 2013 Jan; 14(2):125. PubMed ID: 23447824
    [No Abstract]   [Full Text] [Related]  

  • 47. Two drugs beat back lung tumors.
    Cancer Discov; 2015 Feb; 5(2):100. PubMed ID: 25656878
    [No Abstract]   [Full Text] [Related]  

  • 48. Crizotinib-induced fatal fulminant liver failure.
    van Geel RM; Hendrikx JJ; Vahl JE; van Leerdam ME; van den Broek D; Huitema AD; Beijnen JH; Schellens JH; Burgers SA
    Lung Cancer; 2016 Mar; 93():17-9. PubMed ID: 26898609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MEK/MAPK inhibitors.
    Dy G
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S474-5. PubMed ID: 21102245
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Refining the toxicity profile of crizotinib.
    Solomon B
    J Thorac Oncol; 2014 Nov; 9(11):1596-7. PubMed ID: 25436794
    [No Abstract]   [Full Text] [Related]  

  • 52. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?
    Saijo N
    Nat Clin Pract Oncol; 2005 Jun; 2(6):275. PubMed ID: 16264964
    [No Abstract]   [Full Text] [Related]  

  • 54. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
    Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cyclooxygenase 2 inhibitors and lung carcinoma].
    Spano JP; Chouahnia K; Morère JF
    Bull Cancer; 2004 May; 91 Suppl 2():S109-12. PubMed ID: 15899634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
    Engelman JA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4637-40. PubMed ID: 17671156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crizotinib in anaplastic large-cell lymphoma.
    Gambacorti-Passerini C; Messa C; Pogliani EM
    N Engl J Med; 2011 Feb; 364(8):775-6. PubMed ID: 21345110
    [No Abstract]   [Full Text] [Related]  

  • 58. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
    Costa DB; Kobayashi S; Pandya SS; Yeo WL; Shen Z; Tan W; Wilner KD
    J Clin Oncol; 2011 May; 29(15):e443-5. PubMed ID: 21422405
    [No Abstract]   [Full Text] [Related]  

  • 59. Long-term Survival Associated with Crizotinib in a Lung Cancer Patient with a Pulmonary Artery Embolism.
    Shen Q; Dong XQ; Zhou JY
    Chin Med J (Engl); 2018 Jan; 131(1):111-112. PubMed ID: 29271393
    [No Abstract]   [Full Text] [Related]  

  • 60. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.